Carole B. Miller

11.7k citations

108 papers · 5.2k indexed · 3 hit papers · h-index 31

Hematology top 0.2%
Oncology top 1%
Infectious Diseases top 1%
Epidemiology top 2%
Genetics top 0.5%

Co-authors: Richard J. Jones Steven Piantadosi Martin D. Abeloff Jerry L. Spivak John R. Wingard William G. Merz Mary M. Horowitz Richard F. Ambinder
Topics: Chronic Myeloid Leukemia Treatments (29 papers)Myeloproliferative Neoplasms: Diagnosis and Treatment (28 papers)Chronic Lymphocytic Leukemia Research (23 papers)
Cited by: Hematology Genetics Otorhinolaryngology
Journals: New England Journal of Medicine The Journal of Experimental Medicine Journal of Clinical Oncology
Partner nations: United States Canada United Kingdom

In The Last Decade

Carole B. Miller

107 papers receiving 5.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Micafungin versus Fluconazole for Prophylaxis against Invasive Fungal Infections during Neutropenia in Patients Undergoing Hematopoietic Stem Cell Transplantation

2004 526 citations V. Ratanatharathorn, Daniel E. Stepan et al. Clinical Infectious Diseases profile →
Oral Mucositis and the Clinical and Economic Outcomes of Hematopoietic Stem-Cell Transplantation

2001 516 citations Carole B. Miller, Mary M. Horowitz et al. Journal of Clinical Oncology profile →
Decreased Erythropoietin Response in Patients with the Anemia of Cancer

1990 507 citations Carole B. Miller, Richard J. Jones et al. profile →

Peers

Countries citing papers authored by Carole B. Miller

Since Specialization

Citations

This map shows the geographic impact of Carole B. Miller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carole B. Miller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carole B. Miller more than expected).

Fields of papers citing papers by Carole B. Miller

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carole B. Miller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carole B. Miller. The network helps show where Carole B. Miller may publish in the future.

Co-authorship network of co-authors of Carole B. Miller

This figure shows the co-authorship network connecting the top 25 collaborators of Carole B. Miller. A scholar is included among the top collaborators of Carole B. Miller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carole B. Miller. Carole B. Miller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Safety and Tolerability of Fedratinib (FEDR), an Oral Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate- or High-Risk Myelofibrosis (MF) Previously Treated with Ruxolitinib (RUX): Results from the Phase 3b FREEDOM Trial 2021 ·Blood ·Vikas Gupta,Abdulraheem Yacoub,Srđan Verstovšek,Ruben A. Mesa,Claire Harrison,Giovanni Barosi,Jean‐Jacques Kiladjian,H. Joachim Deeg,Salman Fazal,Lynda Foltz,Ryan J. Mattison,Carole B. Miller,(unknown),(unknown),Christopher Hernandez,Tianhua Wang,Moshe Talpaz	8
2	Hepcidin Suppression By Momelotinib Is Associated with Increased Iron Availability and Erythropoiesis in Transfusion-Dependent Myelofibrosis Patients 2018 ·Blood ·Stephen T. Oh,Moshe Talpaz,Aaron T. Gerds,Vikas Gupta,Srđan Verstovšek,Ruben A. Mesa,Carole B. Miller,Candido E. Rivera,Angela G. Fleischman,Swati Goel,Mark Heaney,Casey L. O’Connell,Murat O. Arcasoy,Yafeng Zhang,Jun Kawashima,Tomas Ganz,Carrie Baker Brachmann	4
3	Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy 2017 ·Leukemia Research ·Srđan Verstovšek,Claire Harrison,Jean‐Jacques Kiladjian,Carole B. Miller,Ahmad Naim,Dilan Paranagama,Dany Habr,Alessandro M. Vannucchi	22
4	Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN Landmark survey 2016 ·BMC Cancer ·Ruben A. Mesa,Carole B. Miller,(unknown),James K. Mangan,(unknown),Salman Fazal,Xiaomei Ma,Wendy Wilson,Dilan Paranagama,(unknown),John Boyle,John Mascarenhas	122
5	Financial Burden of Myeloproliferative Neoplasms on Patients: Results from the MPN Landmark Survey in the United States 2015 ·Blood ·Shreekant Parasuraman,Ahmad Naim,Dilan Paranagama,(unknown),(unknown),John Mascarenhas,James K. Mangan,Salman Fazal,Carole B. Miller,Ruben A. Mesa	2
6	K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate 2010 ·Clinical Cancer Research ·B. Douglas Smith,Yvette L. Kasamon,Jeanne Kowalski,Christopher D. Gocke,Kathleen M. Murphy,Carole B. Miller,Elizabeth Garrett‐Mayer,Hua-Ling Tsai,Qin Lu,Christina Y. Chia,Barbara Biedrzycki,Thomas C. Harding,(unknown),Richard J. Jones,Kristen Hege,Hyam I. Levitsky	77
7	Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation: a comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant Research 2007 ·Bone Marrow Transplantation ·Michael R. Bishop,Brent R. Logan,Sharavi Gandham,Brian J. Bolwell,(unknown),Hillard M. Lazarus,Mark R. Litzow,D I Marks,Peter H. Wiernik,Philip L. McCarthy,Jeffrey A. Russell,Carole B. Miller,Jorge Sierra,Giuseppe Milone,Armand Keating,Fausto R. Loberiza,Sergio Giralt,Mary M. Horowitz,Daniel J. Weisdorf	37
8	Lipid formulations of amphotericin B preserve and stabilize renal function in HSCT recipients 2004 ·Bone Marrow Transplantation ·Carole B. Miller,Edmund K. Waller,Hans-G. Klingemann,María Cecilia Dignani,E. Anaissie,Pablo J. Cagnoni,Peter A. McSweeney,P. Fleck,Steven Fruchtman,Joseph P. McGuirk,Nelson J. Chao	24
9	Micafungin versus Fluconazole for Prophylaxis against Invasive Fungal Infections during Neutropenia in Patients Undergoing Hematopoietic Stem Cell Transplantationbreakdown → 2004 ·Clinical Infectious Diseases ·(unknown),V. Ratanatharathorn,Daniel E. Stepan,Carole B. Miller,Jeffrey H. Lipton,David H. Vesole,Nancy Bunin,Donna A. Wall,J. Hiemenz,Yoichi Satoi,(unknown),Thomas J. Walsh	526
10	Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells 2003 ·Biology of Blood and Marrow Transplantation ·Carol Ann Huff,Ephraim J. Fuchs,Stephen J. Noga,Paul V. O’Donnell,Richard F. Ambinder,Louis F. Diehl,Ivan Borrello,Georgia B. Vogelsang,Carole B. Miller,Ian W. Flinn,Robert A. Brodsky,Deborah Marcellus,Richard J. Jones	25
11	Long-term follow-up of intensive ara-C-based chemotherapy followed by bone marrow transplantation for adult acute lymphoblastic leukemia: impact of induction Ara-C dose and post-remission therapy 2002 ·Leukemia Research ·Eduardo M. Sotomayor,Steven Piantadosi,Carole B. Miller,J. E. Karp,Richard J. Jones,Scott D. Rowley,Scott H. Kaufmann,HG Braine,Philip J. Burke,Steven D. Gore	11
12	Autologous bone marrow transplantation with 4‐hydroperoxycyclophosphamide purging for acute myeloid leukaemia beyond first remission: a 10‐year experience 2002 ·British Journal of Haematology ·B. Douglas Smith,Richard J. Jones,Shing M. Lee,S Piantadosi,Milada S. Vala,(unknown),Steven D. Gore,(unknown),Paul V. O’Donnell,Hayden G. Braine,Georgia B. Vogelsang,Ephraim J. Fuchs,Ian W. Flinn,Robert A. Brodsky,Richard F. Ambinder,Carole B. Miller	11
13	The effect of graft purging with 4-hydroperoxycyclophosphamide in autologous bone marrow transplantation for acute myelogenous leukemia 2001 ·Experimental Hematology ·Carole B. Miller,Philip A. Rowlings,Mei‐Jie Zhang,Richard J. Jones,Steven Piantadosi,Armand Keating,Jamés O. Armitage,Stan Calderwood,Richard E. Harris,John P. Klein,Hillard M. Lazarus,Charles Linker,Kathleen A. Sobocinski,Daniel J. Weisdorf,Mary M. Horowitz	37
14	Refinements of Environmental Assessment During an Outbreak Investigation of Invasive Aspergillosis in a Leukemia and Bone Marrow Transplant Unit 2000 ·Infection Control and Hospital Epidemiology ·Chloe L. Thio,(unknown),William G. Merz,Andrew J. Streifel,(unknown),(unknown),Carole B. Miller,Trish M. Perl	65
15	Philadelphia chromosome-negative engraftment after autologous transplantation with granulocyte-macrophage colony-stimulating factor for chronic myeloid leukemia 1999 ·Biology of Blood and Marrow Transplantation ·Douglas E. Gladstone,Atul Bedi,Carole B. Miller,Stephen J. Noga,Constance A. Griffin,Steven Piantadosi,Pablo J. Cagnoni,Robert A. Brodsky,Benjamin D. Smith,(unknown),(unknown),(unknown)	11
16	Immune modulation in autologous bone marrow transplantation: cyclosporine and gamma-interferon trial 1999 ·Bone Marrow Transplantation ·GB Vogelsang,(unknown),Steven Piantadosi,V Altomonte,Thomas Horn,RJ Jones,Carole B. Miller,Deborah Marcellus,(unknown),AD Hess	16
17	Association of BK virus with failure of prophylaxis against hemorrhagic cystitis following bone marrow transplantation. 1995 ·Journal of Clinical Oncology ·A Bedi,Carole B. Miller,(unknown),Steven N. Goodman,Richard F. Ambinder,Patricia Charache,Ray R. Arthur,(unknown)	207
18	Inefficacy of Low-Dose Continuous Oral Etoposide in Non-Small Cell Lung Cancer 1994 ·American Journal of Clinical Oncology ·Martin S. Blumenreich,(unknown),Carole B. Miller,(unknown),(unknown),(unknown),John Hamm,Janell Seeger,Lee Robinson,Phillip L. Hagan,Daniel Sullivan,Thomas Woodcock	8
19	Evolution of a near-triploid karyotype in a secondary erythroleukemia 1991 ·Cancer Genetics and Cytogenetics ·(unknown),Carole B. Miller,Philip J. Burke,Chandi Griffin	2
20	Immune response to a thymus-dependent form of B512 dextran requires the presence of Lyb-5+ lymphocytes. 1983 ·The Journal of Experimental Medicine ·K E Stein,David A. Zopf,Carole B. Miller,Barbara Johnson,Patricia K. A. Mongini,Aftab Ahmed,W E Paul	28

About Carole B. Miller

Carole B. Miller is a scholar working on Genetics, Hematology and Oncology, having authored 108 papers that have together received 5.2k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (29 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (28 papers) and Chronic Lymphocytic Leukemia Research (23 papers). The work is most often cited by research in Hematology (2.1k citations), Genetics (1.0k citations) and Otorhinolaryngology (331 citations). Carole B. Miller has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Richard J. Jones, Steven Piantadosi, Martin D. Abeloff, Jerry L. Spivak, John R. Wingard, William G. Merz, Mary M. Horowitz, Richard F. Ambinder, Judith E. Karp and Michael G. Rinaldi. Their work appears in journals such as New England Journal of Medicine, The Journal of Experimental Medicine and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact